NASDAQ
127.80USD
+3.81 (+3.07%)
We have scored 31 news catalysts on iRhythm Technologies, Inc. (IRTC) over the past 12 months. The biggest single-day move next to one of them came Jan 31, 2026, when IRTC closed +3.7%: “iRhythm: Structural Shift To Profitable Growth”. Coverage across the window leans negative (average ticker sentiment −0.16). Most of the impact sits in institutional appeal and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.2B
P/E
—
EPS
—
Beta
1.32
52W range
100.7-212
Day range
125.11–128.34
Open
125.11
Prev close
123.99
Volume
550.2K
Avg volume
572.5K
Dividend
0.00
IPO
2016-10-20
Analysts publish price targets on IRTC, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
10 analyst price targets from $150 to $196
as of 2026-09-24
The market is 32% below the median target — more cautious than the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about iRhythm Technologies, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for IRTC: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
iRhythm Technologies, Inc. is a digital healthcare enterprise dedicated to offering portable electrocardiogram (ECG) monitoring solutions to individuals in the United States who face the risk of cardiac arrhythmias. Its primary offering, the Zio service, provides a comprehensive ambulatory cardiac monitoring system. This system ingeniously combines a wireless, patch-based, and wearable biosensor—specifically embodied in products like the Zio XT and AT monitors—with a sophisticated cloud-based data analysis platform. These single-use biosensors precisely record a patient's heartbeats and ECG data, thereby enabling medical professionals to effectively oversee patient heart health and accurately diagnose arrhythmias. Furthermore, iRhythm maintains a strategic development partnership with Verily Life Sciences LLC, focused on pioneering future atrial fibrillation screening, detection, and monitoring innovations. Founded in 2006, the company maintains its corporate headquarters in San Francisco, California.
The price sits 32% below the median analyst target and at the very bottom of the published range, meaning the market has fully absorbed the recent operational improvements but entirely rejects the bullish growth and margin assumptions embedded in those targets.
What the disagreement turns on
Can iRhythm sustain a near-30% revenue growth rate long enough to grow into its valuation, and can the wired data on unit volumes confirm or deny that trajectory?
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $112 on 2026-09-24 — the quote has since moved +14%, so read this as a record of what was priced in then, not now.
